CYTK - サイトキネティクス （Cytokinetics Incorporated）CYTKのニュース
Cytokinetics Incorporated (NASDAQ: CYTK)’s Stock Is Down -2.83% Since The Beginning Of The Year, Likely To Sustain The Trend In 2022 2022/12/09 19:00:00 Marketing Sentinel
During the recent session, Cytokinetics Incorporated (NASDAQ:CYTK)’s traded shares were 0.92 million, with the beta value of the company hitting 1.00. At the last check today, the stock’s price was $37.62, reflecting an intraday gain of 4.50% or $1.62. The 52-week high for the CYTK share is $55.80, that puts it down -48.33 from that … Cytokinetics Incorporated (NASDAQ: CYTK)’s Stock Is Down -2.83% Since The Beginning Of The Year, Likely To Sustain The Trend In 2022 Read More »
Ahead of adcomm, FDA raises uncertainties on benefit-risk profile of Cytokinetics'' potential heart drug 2022/12/09 18:56:08 Endpoints News
The FDA''s Cardiovascular and Renal Drugs Advisory Committee will meet next Tuesday to discuss whether Cytokinetics'' potential heart drug can safely reduce the risk of cardiovascular death and heart failure in patients with symptomatic chronic heart failure with reduced ejection fraction. The drug, known as omecamtiv mecarbil and in development
FDA staff reviewers flag safety concerns over Cytokinetics’ heart drug 2022/12/09 17:47:34 Financial Post
U.S. Food and Drug Administration staff reviewers on Friday identified safety and efficacy concerns about Cytokinetics Inc’s heart drug, according to briefing documents published on the agency’s website. The late-stage data raises concerns about the drug’s dose-limiting risks of heart failure, the reviewers said, adding it is unclear if the study would be enough to […]
CYTK stock dips as FDA posts briefing documents on heart failure therapy (NASDAQ:CYTK) 2022/12/09 14:29:55 Seeking Alpha
Shares of the clinical-stage biotech Cytokinetics (CYTK) fell in the pre-market trading Friday after the FDA briefing documents ahead of an advisory committee meeting scheduled next week…
Cytokinetics Announces Availability of Briefing Documents for FDA Advisory Committee Meeting on Omecamtiv Mecarbil 2022/12/09 13:59:00 GlobeNewswire
SOUTH SAN FRANCISCO, Calif., Dec. 09, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the U.S. Food & Drug Administration (FDA) posted briefing documents for the Cardiovascular and Renal Drugs Advisory Committee (CRDAC) meeting to review the New Drug Application (NDA) for omecamtiv mecarbil, an investigational selective, small molecule cardiac myosin activator for the treatment of heart failure with reduced ejection fraction (HFrEF).
Hot Stocks: IRBT jumps on AMZN merger deal; CYTK rallies; WBD, HYZN drop 2022/08/05 21:52:39 Seeking Alpha
IRBT jumped on a merger deal with AMZN. CYTK climbed after its quarterly update. WBD dropped on its earnings news. HYZN plunged.
Cytokinetics Records $89M Q2 Sales On Deferred Mavacamten Revenues, Forecasts FY22 Cash Of Over $800M 2022/08/05 12:16:40 Benzinga
Cytokinetics Inc (NASDAQ: CYTK ) reported Q2 sales of $88.96 million compared to $2.84 million a year ago, primarily due to the recognition of $87 million deferred revenue for sales royalties of mavacamten as a result of the extinguishment of royalty obligations. The analysts estimated sales of $3.63 million. The company reported an EPS loss of $(0.23), down from $(0.86) a year … Full story available on Benzinga.com
Cytokinetics PT Raised to $53 at JMP Securities 2022/08/05 07:33:02 Investing.com
https://www.investing.com/news/pro/cytokinetics-pt-raised-to-53-at-jmp-securities-432SI-2864530
Recap: Cytokinetics Q2 Earnings 2022/08/04 21:31:29 Benzinga
Cytokinetics (NASDAQ: CYTK ) reported its Q2 earnings results on Thursday, August 4, 2022 at 04:00 PM. Here''s what investors need to know about the announcement. Earnings Cytokinetics beat estimated earnings by 77.45%, reporting an EPS of $-0.23 versus an … Full story available on Benzinga.com
Cytokinetics GAAP EPS of -$0.23 beats by $0.81, revenue of $88.97M beats by $85.24M (NASDAQ:CYTK) 2022/08/04 20:13:15 Seeking Alpha
Cytokinetics press release (CYTK): Q2 GAAP EPS of -$0.23 beats by $0.81.Revenue of $88.97M (+3032.7% Y/Y) beats by $85.24M.Revised 2022 Financial Guidance: The company today revised…
Cytokinetics Incorporated (NASDAQ:CYTK) Stock Dropped -13.80% Year-To-Date, What Analysts Expect Next? 2022/07/01 11:00:00 Marketing Sentinel
In last trading session, Cytokinetics Incorporated (NASDAQ:CYTK) saw 10.35 million shares changing hands with its beta currently measuring 1.05. Company’s recent per share price level of $39.29 trading at -$9.45 or -19.39% at ring of the bell on the day assigns it a market valuation of $3.38B. That closing price of CYTK’s stock is at … Cytokinetics Incorporated (NASDAQ:CYTK) Stock Dropped -13.80% Year-To-Date, What Analysts Expect Next? Read More »
Cytokinetics prices $450M of convertible debt offering 2022/07/01 08:00:27 Seeking Alpha
Cytokinetics, Incorporated (CYTK) has priced its offering of $450.0M aggregate principal amount of 3.50% convertible senior notes due 2027
Cytokinetics Announces Pricing of $450 Million Convertible Senior Notes Offering 2022/07/01 07:35:00 GlobeNewswire
SOUTH SAN FRANCISCO, Calif., July 01, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (“Cytokinetics”) (Nasdaq: CYTK) today announced the pricing of its offering of $450.0 million aggregate principal amount of 3.50% convertible senior notes due 2027 (the “notes”) in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”).